KALV Quote, Financials, Valuation and Earnings

CVRx has a net margin of -- compared to KalVista Pharmaceuticals's net margin of -97.95%. KalVista Pharmaceuticals's return on equity of -- beat CVRx's return on equity of -84.64%.

KalVista Pharmaceuticals has a consensus price target of $28.50, signalling upside risk potential of 205.33%. On the other hand CVRx has an analysts' consensus of $18.17 which suggests that it could grow by 33.19%. Given that KalVista Pharmaceuticals has higher upside potential than CVRx, analysts believe KalVista Pharmaceuticals is more attractive than CVRx.

KalVista Pharmaceuticals has a beta of 0.859, which suggesting that the stock is 14.105% less volatile than S&P 500. In comparison CVRx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

KalVista Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals pays -- of its earnings as a dividend. CVRx pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals quarterly revenues are --, which are smaller than CVRx quarterly revenues of $13.4M. KalVista Pharmaceuticals's net income of -$42.3M is lower than CVRx's net income of -$13.1M. Notably, KalVista Pharmaceuticals's price-to-earnings ratio is -- while CVRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals is 30.44x versus 6.24x for CVRx. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to KalVista Pharmaceuticals's net margin of 10.05%. KalVista Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.62%.

KalVista Pharmaceuticals has a consensus price target of $28.50, signalling upside risk potential of 205.33%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 7.53%. Given that KalVista Pharmaceuticals has higher upside potential than Electromed, analysts believe KalVista Pharmaceuticals is more attractive than Electromed.

KalVista Pharmaceuticals has a beta of 0.859, which suggesting that the stock is 14.105% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

KalVista Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. KalVista Pharmaceuticals's net income of -$42.3M is lower than Electromed's net income of $1.5M. Notably, KalVista Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 42.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals is 30.44x versus 4.80x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -- compared to KalVista Pharmaceuticals's net margin of 99.62%. KalVista Pharmaceuticals's return on equity of -- beat Nuwellis's return on equity of -918.02%.

KalVista Pharmaceuticals has a consensus price target of $28.50, signalling upside risk potential of 205.33%. On the other hand Nuwellis has an analysts' consensus of -- which suggests that it could grow by 1255.93%. Given that Nuwellis has higher upside potential than KalVista Pharmaceuticals, analysts believe Nuwellis is more attractive than KalVista Pharmaceuticals.

KalVista Pharmaceuticals has a beta of 0.859, which suggesting that the stock is 14.105% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.377%.

KalVista Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals quarterly revenues are --, which are smaller than Nuwellis quarterly revenues of $2.4M. KalVista Pharmaceuticals's net income of -$42.3M is lower than Nuwellis's net income of $2.4M. Notably, KalVista Pharmaceuticals's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals is 30.44x versus 0.07x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to KalVista Pharmaceuticals's net margin of -17.98%. KalVista Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

KalVista Pharmaceuticals has a consensus price target of $28.50, signalling upside risk potential of 205.33%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 326.95%. Given that Xtant Medical Holdings has higher upside potential than KalVista Pharmaceuticals, analysts believe Xtant Medical Holdings is more attractive than KalVista Pharmaceuticals.

KalVista Pharmaceuticals has a beta of 0.859, which suggesting that the stock is 14.105% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

KalVista Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. KalVista Pharmaceuticals's net income of -$42.3M is lower than Xtant Medical Holdings's net income of -$5M. Notably, KalVista Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals is 30.44x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.